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Introduction
Dexmedetomidine (Dex) is a sedative drug approved as
dexdor® (Orion Pharma, Finland) for ICU sedation in
adults in the European Union in 2011. This observational,
retrospective drug utilisation study was requested by the
Committee for Human Medicinal Products for Human
Use of the European Medicines Agency to investigate Dex
use in clinical practice.
Objectives
The objective of the study was to evaluate how Dex is
used in the EU, with particular focus on off-label use
including the paediatric population.
Methods
Study countries/sites were chosen by a blinded multi-
national, multi-specialist, independent group from those
with highest Dex use, based on sales. All patients treated
with Dex during the enrollment period were to be
included. Anonymised data on demographics, treatment
indication, dosing, concomitant medications and treat-
ment effectiveness were collected retrospectively.
Informed consent was waived to avoid influence of the
study on the prescribing of Dex.
Results
Data from 2000 patients were collected from 16 hospitals
in 4 EU countries (Finland 750, Poland 505, Germany 470,
Austria 275) between June 2013 and December 2014. The
median age was 62 years (males 70.2%). The proportion of
paediatric patients was 5.2% with the highest incidence in
Austria and Finland. Dex was primarily used in adult ICU
(86.0%) for ICU sedation (78.6%) and mostly dosed
according the label. Overall in 84.9% of administrations
the intended sedative effect was obtained. The most com-
mon clinical situations in the ICU in which Dex was used
varied between countries but was predominantly agitation
despite existing sedation, delirium and difficult to wean
from the ventilator. Other clinical objectives included
reducing/replacing other sedatives and facilitating sleep.
Conclusions
This drug utilisation study indicates that Dex is mostly
used according to the terms of its product licence,
although a variable degree of use was also seen in other
settings and populations.
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